30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Clinical trial NCT01183013 · COMPLETED

Trial details

NCT number: NCT01183013
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diabetes Mellitus, Type 2

Start date: 2010-08-01
Primary completion: 2013-02-01
Enrollment: 936

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.